Clincosm LogoSign in Get a demo

The Prevelance of Pulmonary Manifestation in Patients With Inflammatory Bowel Disease

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04613466
Collaborator
(none)
60
Enrollment
18
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Bronchopulmonary manifestations signs and symptoms are variable extraintestinal manifestations of IBD.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Several cases like bronchiactsis, bronchitis, tracheobronchitis and broncholitis. None of this complications are specific for either crohns or ulcerative , however the majority of cases are related to ulcerative colitis.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    60 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    The Prevelance of Pulmonary Manifestations in Patients With Inflammatory Bowel Disease
    Anticipated Study Start Date :
    Dec 1, 2020
    Anticipated Primary Completion Date :
    Dec 1, 2021
    Anticipated Study Completion Date :
    Jun 1, 2022

    Outcome Measures

    Primary Outcome Measures

    1. The presence of pulmonary manifestations in IBD patients [1 year]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 60 Years
    Sexes Eligible for Study:
    All

    Inclusion Criteria:All patients diagnosed ulcerative colitis and crohns disaese on conventional treatment and biological treatment -

    Exclusion Criteria:no exclusion criteria

    -

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Assiut University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Hayam Fathy Nasr, clinical doctor of internal medicine, Assiut University
    ClinicalTrials.gov Identifier:
    NCT04613466
    Other Study ID Numbers:
    • Gateroentrolgy unit
    First Posted:
    Nov 3, 2020
    Last Update Posted:
    Nov 13, 2020
    Last Verified:
    Nov 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Intestinal Diseases
    Inflammatory Bowel Diseases

    Study Results

    No Results Posted as of Nov 13, 2020